Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Pneumocystis in COPD (the TOPIC Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Carries the diagnosis of COPD and admitted for and admitted with AECOPD to Beaumont, Royal Oak (AECOPD requires increased cough, increased sputum production, and shortness of breath +/- increased oxygen needs from baseline)~* Able to produce a sputum sample~* Men or women, age ≥ 40 and \< 90~* Previously enrolled in the EPIC Study and positive for Pneumocystis jirovecii detected in their sputum~* Currently treated with steroids~* Kidney function not severely impaired (CrCl ≥ 60)~* AST and ALT ≤5x upper limit of normal~* Willing and able to consent to the study~Exclusion Criteria:~* Current diagnosis of pneumonia or COVID-19~* Allergy or hypersensitivity to trimethoprim-sulfamethoxazole~* Current ICU admission or mechanical ventilation~* Active cancer or chemotherapy (except non-melanoma skin cancer)~* Other potentially confounding pulmonary diagnosis~* HIV, leukopenia, neutropenia, or other immunosuppressive condition or current use of immunosuppressive medications~* Presence of gastrointestinal tract abnormalities that would prevent absorption of medications~* Patients with concomitant infection requiring antibiotics active against Pneumocystis jirovecii~* Concomitant use of coumadin, phenytoin, pioglitazone, repaglinide, rosiglitazone, glipizide or glyburide~* Megaloblastic anemia due to folate deficiency~* Pregnancy~* Life expectancy less than 3 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- TMP-SMX (Type: EXPERIMENTAL): Suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
- Placebo (Type: PLACEBO_COMPARATOR): Suspension with placebo by mouth every 12 hours for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).